| 36th week of 2019 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20190269764 | POWDER FORMULATION - The invention relates to sterile powder compositions suitable for medical use comprising thrombin and fibrinogen, and to methods for producing the same, wherein the thrombin powder is produced from a liquid feedstock, wherein the feedstock comprises a solution or a suspension of thrombin, preferably a solution, wherein the powder is produced by removal of liquid by a process selected from aseptic spray drying or aseptic fluid bed drying, and wherein the powder resulting from removal of liquid from the feedstock exhibits at least 80% of the thrombin potency or activity of the liquid feedstock, and wherein the fibrinogen powder is produced by removal of liquid from a feedstock, wherein the feedstock comprises a solution or a suspension of fibrinogen, preferably a solution, by aseptic spray drying or aseptic fluid bed drying, and wherein said composition is packaged as a sterile final pharmaceutical product for medical use. | 2019-09-05 |
| 20190269765 | METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS - The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-alpha inhibitor proteins (lalps), including, e.g., inter-alpha inhibitor (lal) and/or pre-alpha inhibitor (Pal). | 2019-09-05 |
| 20190269766 | TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY - The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual. | 2019-09-05 |
| 20190269767 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-09-05 |
| 20190269768 | T Cell Expansion - A method for generating or expanding a population of T cells specific for a virus by a method comprising: stimulating T cells by culture in the presence of antigen presenting cells (APCs) presenting a peptide of the virus, wherein at least 10% of the media in which the cells are cultured is conditioned media obtained from a stimulation culture comprising T cells and APCs presenting a peptide of the virus. Also disclosed are methods for accelerating the rate of expansion of a virus-specific T cell population, and methods for treating or preventing diseases or disorders using the generated or expanded T cell population. | 2019-09-05 |
| 20190269769 | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS - The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-09-05 |
| 20190269770 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-09-05 |
| 20190269771 | PEPTIDE MIMOTOPE THAT INDUCES AN IMMUNE RESPONSE AGAINST MYCOBACTERIUM TUBERCULOSIS LIPOARABINOMANNAN (LAM) - The present invention concerns methods and compositions for treating or preventing infection or dissemination of the bacterium | 2019-09-05 |
| 20190269772 | HEAT-RESISTANT PROTECTIVE AGENT, ROOM-TEMPERATURE-PRESERVED LIVE CLASSICAL SWINE FEVER VACCINE, AND PREPARATION METHOD AND APPLICATION THEREOF - A thermostable formula comprises the following components in percentage by mass: 1% to 5% raffinose, 5% to 10% maltose, 15% to 30% saccharose, 1% to 5% lactose, 1% to 5% glucose, 0.1% to 1.5% polysorbate 80, 0.1% to 0.5% polyethylene glycol 8000, 0.5% to 3% tyrosine, 3% to 6% silk fibroin, and the balance of water for injection. It further discloses a room-temperature-preserved live classical swine fever vaccine and a preparation method thereof, wherein the live classical swine fever vaccine is obtained by mixing the thermostable formula with a live classical swine fever virus solution and then carrying out gradient vacuum drying. The vaccine prepared according to the present invention has a dried foam appearance and presents a glass-layer like structure under a scanning electron microscope, has a glass transition temperature up to more than 50° C. | 2019-09-05 |
| 20190269773 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION - Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum. | 2019-09-05 |
| 20190269774 | LIQUID ALLERGEN COMPOSITIONS AND METHODS FOR MAKING THE SAME - Liquid mixed allergen compositions of two or more different allergens are provided. Also provided are methods of making liquid mixed allergen compositions and administering a liquid mixed allergen composition to a subject. | 2019-09-05 |
| 20190269775 | COMPOSITIONS AND METHODS OF TREATING CANCER - The present invention provides compositions and methods for treating cancer. | 2019-09-05 |
| 20190269776 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF - The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer. | 2019-09-05 |
| 20190269777 | COMBINATION OF AN OXIDANT, A PHOTOSENSITIZER AND A WOUND HEALING AGENT FOR ORAL DISINFECTION AND TREATMENT OF ORAL DISEASE - The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier. | 2019-09-05 |
| 20190269778 | Acetylcysteine Compositions and Methods of use Thereof - A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed. | 2019-09-05 |
| 20190269779 | Liquid Formulation of Long-Lasting Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment - The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. In addition, the oxyntomodulin conjugate of the invention comprises oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin. | 2019-09-05 |
| 20190269780 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE - Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided. | 2019-09-05 |
| 20190269781 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE - Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided. | 2019-09-05 |
| 20190269782 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE - Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided. | 2019-09-05 |
| 20190269783 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS - The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer. | 2019-09-05 |
| 20190269784 | Selective Inhibitors of the Polo-Like Kinase 1 Polo-Box Domain - Inhibitors that are specific for the PBD domain of the PLK1 protein are described. The inhibitors include fragment ligated inhibitors that include one or more amino acids of a starting peptide upon which the inhibitors are based and also include non-peptidic inhibitors. The inhibitors include a benzoic acid-based derivative that mimics the structure activity relationship of amino acid residues of known peptide inhibitors. The inhibitors exhibit high selectivity for the PLK1 isotype. | 2019-09-05 |
| 20190269785 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME - Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity. | 2019-09-05 |
| 20190269786 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 2019-09-05 |
| 20190269787 | IGG FC FRAGMENT FOR A DRUG CARRIER AND METHOD FOR THE PREPARATION THEREOF - Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug. | 2019-09-05 |
| 20190269788 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER - The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer. | 2019-09-05 |
| 20190269789 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY - The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer. | 2019-09-05 |
| 20190269790 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY - The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer. | 2019-09-05 |
| 20190269791 | ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES - The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same. | 2019-09-05 |
| 20190269792 | NANOPARTICLE COMPOSITIONS COMPRISING CD38 AND METHODS OF USE THEREOF - The present disclosure discloses compositions, and methods of making and using nanoparticles to treat multiple myeloma. | 2019-09-05 |
| 20190269793 | METHOD FOR CELLULAR RNA EXPRESSION - The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells. | 2019-09-05 |
| 20190269794 | AFFENADENOVIRUS (GORILLA) OR ADENOVIRAL VECTORS AND METHODS OF USE - The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein. | 2019-09-05 |
| 20190269795 | COMPOSITIONS AND METHODS FOR THE MANUFACTURE OF LIPID NANOPARTICLES - The invention relates to methods, processes and apparatuses for the manufacture of lipid nanoparticles having a therapeutic payload. | 2019-09-05 |
| 20190269796 | PROMOTER FOR CELL-SPECIFIC GENE EXPRESSION AND USES THEREOF - The present invention refers to nucleotide sequences used for driving the expression of a therapeutic gene, preferably FVIII and/or its variants specifically in endothelial cells and/or hematopoietic, preferably myeloid cells. The sequences are useful for gene and/or cell therapy, preferably for treating hemophilia, more preferably type A hemophilia. | 2019-09-05 |
| 20190269797 | GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES - Provided are methods of treating a lysosomal storage disorder in a mammal which method includes administering AAV particles encoding a polypeptide to the central nervous system of the mammal. AAV particles may be delivered by direct injection into the brain, spinal cord, cerebral spinal fluid or a portion thereof for expression. | 2019-09-05 |
| 20190269798 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 - The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone. | 2019-09-05 |
| 20190269799 | METHOD FOR IMPROVING NEUROLOGICAL FUNCTION IN MPSI AND MPSII AND OTHER NEUROLOGICAL DISORDERS - A method to prevent, inhibit or treat one or more neurological symptoms associated with a central nervous system disorder, e.g. MPSI or MPSII by, for example, intrathecally, intracerebroventricularly or intravenously administering a rAAV encoding gene product associated with the disease, e.g., administering to an adult mammal in which the gene product is absent, defective or present at a reduced level relative to a mammal without the disease. | 2019-09-05 |
| 20190269800 | IMMUNOADSORPTION - Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb. | 2019-09-05 |
| 20190269801 | SIMVASTATIN AND CHEMOTHERAPEUTIC CONJUGATES WITH A HEPTAMETHINE CARBOCYANINE DYE RESENSITIZE HUMAN TUMORS TO HORMONAL ANTAGONISTS AND CHEMOTHERAPY - This application relates to dye-therapeutic moiety conjugates for imaging, targeting, and treating cancerous cells and/or tumors. | 2019-09-05 |
| 20190269802 | THERANOSTIC NUCLEIC ACID BINDING FLUORESCENT NANOPROBES AND USES THEREOF - The present disclosure provides nucleic acid binding nanoprobes having one or more fluorochromes and a polymer, where each of the fluorochromes is connected to the polymer, and methods of using the same. | 2019-09-05 |
| 20190269803 | CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME, AND COMPOSITION COMPRISING CONJUGATE - The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed. | 2019-09-05 |
| 20190269804 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT - The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment. | 2019-09-05 |
| 20190269805 | SOLVENT-FREE GADOLINIUM CONTRAST AGENTS - Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents. | 2019-09-05 |
| 20190269806 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION - The present invention is directed to | 2019-09-05 |
| 20190269807 | SOLUBLE TCR MOLECULES AND METHODS OF USE - Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells. | 2019-09-05 |
| 20190269808 | PATHOGEN REDUCED PLATELET COMPOSITIONS AND RELATED METHODS - Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials. | 2019-09-05 |
| 20190269809 | BIOSECURITY SYSTEM FOR AN AGRICULTURAL DWELLING - Sanitizing an agricultural facility by placing a chamber having an open interior within the agricultural facility. An item is placed within an open interior of the chamber and a door is interlocked. Then light having a spectral content within a narrow range of wavelengths is provided from at least one lighting device toward the item for a predetermined amount of time to inactivate a microorganism. Simultaneously, ozone may be discharged into the open interior to sanitize the item. Before the door unlocks the ozone within the interior of the chamber is directed to a filter for forming oxygen. Sanitizing the agricultural facility by detect humans, and in response, providing a first light with one spectral content when the human is detected, and providing a second light with a different spectral content within a narrow range of wavelengths to inhibit bacteria growth when humans are not detected. | 2019-09-05 |
| 20190269810 | MEDICAL DEVICE - The present invention relates to a medical device, in particular a blood treatment device and in particular a dialysis machine, having at least one handle arrangement, in particular a handle arrangement for a door, wherein the handle arrangement has at least one handle that is configured in ring shape; and wherein the handle arrangement furthermore has at least one disinfection unit that works with light, preferably with UV light, and that is arranged to disinfect the handle, with the handle arrangement furthermore having at least one drive unit that is configured to move the handle along the disinfection unit. | 2019-09-05 |
| 20190269811 | Aromatherapy Vaporization Device - A novel herbal vaporization device (HVD) and method is disclosed. The HVD includes a recharging unit for storing therein of a vaporization unit having a heating chamber disposed at a first end thereof for receiving of loose leaf herbal material and for providing of heat thereto, the vaporization unit comprising a second end disposed opposite the first end with a fluid pathway between the two ends. In a first mode of operation the vaporization unit is for being recharged from the recharging unit and in a second mode of operation the vaporization unit is for use in vaporizing of loose leaf herbal material inserted into the heating chamber for having at least partially vaporized loose leaf herbal material and ambient air to flow through the fluid pathway. | 2019-09-05 |
| 20190269812 | LONG-ACTING DEODORIZATION OF NOXIOUS ODORS USING A WATER-BASED DEODORIZING SOLUTION IN AN ULTRASONIC DISPENSER - A long-acting ultrasonic dispenser that effuses a water-based deodorizer solution into ambient air as a dry fog in a closed environment, and a method for deodorizing noxious odors in that closed environment by the dry fog. The dry fog, containing the deodorizer, chemically reacts with materials producing the odors, thereby neutralizing them. The dispenser contains an electronic ultrasonic wave generator comprising a piezoelectric crystal and an ultrasonic membrane, which is always submerged under liquid. As the liquid evaporates, droplets larger than five microns are filtered out, and the remaining dry fog is emitted into the air. The dispenser is connected to a large reservoir. When the liquid level reaches a minimum permissible height, additional deodorizer solution is pumped into the dispenser. This system is ideal for use with central air conditioners in large office buildings to eliminate odors over a long period of time with minimum maintenance. | 2019-09-05 |
| 20190269813 | DEVICE FOR ADSORBING ODOURS - The invention relates to a device for adsorbing odours comprising an absorbent layer and an adsorbent layer, said adsorbent layer being provided with a material permeable to volatile organic compounds (VOCs) and an adsorbent particulate filler comprising at least one spice. Such a device is particularly useful for adsorbing and masking body odours. | 2019-09-05 |
| 20190269814 | PRESSURE-SENSITIVE ADHESIVE AGENT FOR SKIN, PRESSURE-SENSITIVE ADHESIVE SHEET FOR SKIN, AND FACE PLATE OF OSTOMY APPLIANCE - [Objective] | 2019-09-05 |
| 20190269815 | YARNS AND FIBERS OF POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF, AND METHODS OF USE THEROF - Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline. | 2019-09-05 |
| 20190269816 | ORIENTED IMPLANTS CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMER, AND METHODS OF USE THEREOF - Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline. | 2019-09-05 |
| 20190269817 | SURGIAL MESH IMPLANTS CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF - Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline. | 2019-09-05 |
| 20190269818 | SEALANT FOAM COMPOSITIONS FOR LUNG APPLICATIONS - The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL. | 2019-09-05 |
| 20190269819 | SEALANT FOAM COMPOSITIONS FOR LUNG APPLICATIONS - The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL and wherein PEG-SG portion is composed of a blend of 2 PEG-SG different in arm number or arm lengths. | 2019-09-05 |
| 20190269820 | BIOLOGICAL ADHESIVES AND SEALANTS AND METHODS OF USING THE SAME - This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition. | 2019-09-05 |
| 20190269821 | Delivery Scaffolds and Related Methods of Use - The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening). | 2019-09-05 |
| 20190269822 | HERNIA REPAIR, BREAST RECONSTRUCTION AND SLING DEVICES CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF - Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline. | 2019-09-05 |
| 20190269823 | METHOD AND APPARATUS FOR TREATING BONE FRACTURES, AND/OR FOR FORTIFYING AND/OR AUGMENTING BONE, INCLUDING THE PROVISION AND USE OF COMPOSITE IMPLANTS, AND NOVEL COMPOSITE STRUCTURES WHICH MAY BE USED FOR MEDICAL AND NON-MEDICAL APPLICATIONS - A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water. | 2019-09-05 |
| 20190269824 | METHOD FOR PRODUCING SUSPENDED FORM OF GROUND DECELLULARIZED EXTRACELLULAR MATRIX - The present invention relates to the field of pharmaceutics and medicine, in particular, to a method for producing a suspended form of ground decellularized extracellular matrix with size-controlled structural components, the suspended form not 5 requiring pre-hydration, and to a product produced by this method, for stimulation of reparative regeneration of tissues. | 2019-09-05 |
| 20190269825 | ORGAN PRODUCTION METHOD - The present invention provides an organ production method including a step of tissue-specifically removing a first portion of an organ of a non-human animal partway through development thereof; a step of transplanting, into a region from which the first portion has been removed, an organ precursor cell which is allogeneic or xenogeneic to the non-human animal; and a step of advancing development of the organ, which is a step in which the transplanted organ precursor cell is differentiated and matured to form a part of the organ. | 2019-09-05 |
| 20190269826 | Method Of Corneal Transplantation Or Corneal Inlay Implantation With Cross-Linking - A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) forming a flap in a cornea of an eye so as to expose a stromal tissue of the cornea underlying the flap; (ii) pivoting the flap so as to expose the stromal tissue of the cornea underlying the flap; (iii) inserting an implant under the flap so as to overlie the stromal tissue of the cornea, wherein the implant is cross-linked so as to prevent an immune response to the implant and/or rejection of the implant by the patient; and (iv) covering the cross-linked implant with the flap, the cross-linked implant being surrounded entirely by the stromal tissue of the cornea. | 2019-09-05 |
| 20190269827 | CROSS-LINKED BIOPROSTHETIC TISSUE USING BIO-ORTHOGONAL BINDING PAIRS - Methods for treating a bioprosthetic tissue and treated bioprosthetic tissue are described. The methods comprise contacting the biological tissue with an anchor compound, the anchor compound comprising first and second functional groups. The first functional group is reactive with and couples a tissue functional group associated with the biological tissue. The second functional group is one of a bio-orthogonal binding pair. The biological tissue coupled to the anchor compound is then exposed to a linking compound. The linking compound comprises at least two functional groups, each comprising the other one of the bio-orthogonal binding pair. In a preferred embodiment, the bio-orthogonal binding pair is an azide and an acetylene. The method can be performed in the presence of a catalyst, preferably a copper catalyst. Alternatively, the method can be performed in the absence of a catalyst, wherein the acetylene is incorporated in a ring-strained cyclic compound, such as cyclooctyne. | 2019-09-05 |
| 20190269828 | IMPLANT AND KIT FOR TREATMENT OF BONE LESION SITE, AS WELL AS METHOD FOR TREATING BONE LESION SITE - The present invention pertains to an implant for treatment of a bone lesion site, the implant including a polymer porous film and a layer containing a biocompatible material, wherein the polymer porous film is a polymer porous membrane of a three-layer structure having a porous surface layer A, a porous surface layer B, and a macrovoid layer interposed between the surface layer A and the surface layer B; the average pore diameter of the pores in surface layer A is smaller than the average pore diameter of the pores in surface layer B; the macrovoid layer has a partition joined to the surface layers A and B and a plurality of macrovoids enclosed by the partition and the surface layers A and B; and the pores in the surface layers A and B communicate with the macrovoids. | 2019-09-05 |
| 20190269829 | BONE GROWTH FACILITATION DEVICE AND METHODS OF USE - The instant disclosure is directed to devices and methods for facilitating bone growth. In one embodiment, a device may include a porous flexible tube comprising an electrospun fiber. The porous flexible tube may also comprise a closed end. The device may further comprise a filler material at least partially encased by the porous flexible tube. A method of manufacturing such a device may comprise electrospinning a polymer solution onto an end of a cylindrical mandrel to form the porous flexible tube, and removing the porous flexible tube from the end of the cylindrical mandrel. A method of facilitating bone growth may comprise obtaining such a device, and implanting the porous flexible tube into a subject's bone defect. | 2019-09-05 |
| 20190269830 | IMPLANTABLE MEDICAL DEVICES HAVING COATING LAYERS WITH ANTIMICROBIAL PROPERTIES BASED ON NANOSTRUCTURED HYDROXYAPATITES - An implantable medical device may include a coating layer that includes a nanostructured hydroxyapatite doped with zinc ions and functionalized with lactoferrin. A process for coating an implantable medical device may include: providing an electrolytic bath; immersing a cathode and an anode in the electrolytic bath, the cathode including the implantable medical device; and allowing direct electric current to pass through the electrolytic bath so as to obtain electrolytic deposition on the implantable medical device of nanostructured hydroxyapatite doped with zinc ions. The electrolytic bath may include calcium ions, phosphate ions, and the zinc ions. The electrolytic bath also may include lactoferrin. The process may further include depositing lactoferrin on the implantable medical device coated with the nanostructured hydroxyapatite doped with the zinc ions. | 2019-09-05 |
| 20190269831 | COATING FOR MEDICAL EQUIPMENT AND ENDOSCOPE - A coating for medical equipment includes: an isocyanate-curable coating composition; and a radical scavenger. | 2019-09-05 |
| 20190269832 | MACRO-ENCAPSULATED THERAPEUTIC CELLS, DEVICES, AND METHODS OF USING THE SAME - Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease. | 2019-09-05 |
| 20190269833 | Removable Manifold For A Medical/Surgical Waste Collection Unit - A manifold apparatus and method of opening a valve in a medical/surgical waste collection unit. The manifold includes a base at a proximal end with the base defining an opening off center from an axis of the manifold. The manifold further includes two arcuately spaced tabs, each subtending arcs having different arcuate lengths. The manifold is positioned such that the tabs mate with at least two slots of a lock ring of the waste collection unit so as to cause the opening of the manifold to be, upon insertion into a bore of the waste collection unit, in a specific rotational alignment in the bore. The manifold is rotated within the bore to cause a valve disk to move between a first position in which the valve disk blocks fluid flow through the receiver and a second position in which the valve disk allows fluid flow through the receiver. | 2019-09-05 |
| 20190269834 | SYSTEMS AND METHODS FOR MECHANICAL DISPLACEMENT OF AN ESOPHAGUS - An example assembly for use with a vacuum system and an esophageal positioning device esophageal positioning device includes an introducer, in which the esophageal positioning device includes a handle, a first segment, a second segment and an articulation driving mechanism. The first segment being coupled to the handle. The second segment being pivotally connected to the first segment. The articulation driving mechanism being configured to pivot the second segment about the first segment upon articulation. | 2019-09-05 |
| 20190269835 | REDUCED PRESSURE THERAPY DEVICES - Described generally herein are tissue therapy devices, which may comprise a sealant layer and a suction apparatus. The sealant layer functions so as to create a sealed enclosure between it and the surface of a patient by forming, preferably, an airtight seal around an area of tissue that requires negative pressure therapy. The tissue therapy device may comprise a suction apparatus. The suction apparatus is typically in fluid communication with the sealant layer and functions so as to reduce the amount of pressure present underneath the sealant layer. The reduced pressure is self-created by the suction apparatus. Together the sealant layer and the suction apparatus preferably create a closed reduced pressure therapy system. Preferably, the pressure under the sealant layer is reduced by expanding the volume of the enclosure space and thereby decreasing the density of the air molecules under the sealant layer. | 2019-09-05 |
| 20190269836 | INTERFACES, SYSTEMS, AND METHODS FOR USE IN REDUCED PRESSURE TISSUE TREATMENT - Systems and devices for treating a tissue site may include an interface adapted to provide a reduced pressure to a dressing. The interface may include a positive-pressure channel for delivering a positive pressure from a positive-pressure port to a positive pressure outlet. The positive-pressure channel may include a constricted portion configured to provide a pressure drop. The interface may additionally include a reduced-pressure channel adapted to deliver reduced pressure to the dressing that substantially corresponds to the pressure drop. The reduced-pressure channel may be fluidly coupled between the positive pressure channel and a side of the interface body adapted to face the dressing. Other systems and devices are disclosed. | 2019-09-05 |
| 20190269837 | VENTRICULAR ASSIST ASSEMBLY, SYSTEM, AND METHOD - An implantable anastomotic assembly, which is configured to be attached to cardiovascular tissue, includes a connection interface, a plurality of outer plates, and a plurality of connectors configured to extend between and interconnect the connection interface and the plurality of outer plates, respectively, according to various embodiments. The connection interface is separate from and non-contiguous with the plurality of outer plates, according to various embodiments. | 2019-09-05 |
| 20190269838 | Wearable Accessory for Ventricular Assist System - The invention relates generally to wearable accessory carriers for mechanical circulatory support systems, and more specifically relates to belts for carrying peripheral components of a VAD. Such wearable accessory carriers may be suitable for carrying and retaining peripheral components of the VAD in a safe, comfortable, and convenient manner. In certain aspects, the invention provides a wearable accessory carrier configured as an elastic belt with several pockets for holding peripheral components. In other aspects, a wearable accessory carrier may be configured as a belt with a magnetic strip configured to carry one or more modular compartments or pockets for holding peripheral components via magnetic attachment. The wearable accessory carriers disclosed herein may be sized to fit around or configured to be worn on a patient's waist, lower or upper torso, thigh, calf, arm, or other limb. | 2019-09-05 |
| 20190269839 | FORCE TRANSDUCTING IMPLANT SYSTEM FOR THE MITIGATION OF ATRIOVENTRICULAR PRESSURE GRADIENT LOSS AND THE RESTORATION OF HEALTHY VENTRICULAR GEOMETRY - An implant system for restoring and improving physiological intracardiac flow in a human heart is provided including a force transducting, structurally stabilizing, and functionally assisting ventricular inflatable cardiac implant within a human heart for restoring and improving physiologic intracardiac flow, restoring the ventricular vortex, preventing atrioventricular pressure gradient loss, mitigating valvular regurgitation, and utilizing native energy and force, via force transduction, to restore geometric elliptical proportion and function to the atria, the ventricles and ventricular walls, and the valvular apparatus itself. | 2019-09-05 |
| 20190269840 | BLOOD PUMPS - Apparatus and methods are described including a blood pump ( | 2019-09-05 |
| 20190269841 | LOW RESISTANCE MICROFABRICATED FILTER - The present technology provides micro fabricated filtration devices, methods of making such devices, and uses for microfabricated filtration devices. The devices may allow diffusion to occur between two fluids with improved transport resistance characteristics as compared to conventional filtration devices. The devices may include a compound structure that includes a porous membrane overlying a support structure. The support structure may define a cavity and a plurality of recesses formed in a way that can allow modified convective flow of a first fluid to provide improved diffusive transport between the first fluid and a second fluid through the membrane. | 2019-09-05 |
| 20190269842 | VASCULAR ACCESS PORT SYSTEMS AND METHODS - In certain systems disclosed herein, one or more of a first vascular access port and a second vascular access port can be selected by a customer. Each of the first and second vascular access ports can be implanted subcutaneously within a patient, and each can include a base configured to be attached to a vessel, a body that extends away from the base, and a guidance passageway that extends through the body and the base and includes a funnel region. A maximum height defined by the base and body of the second vascular access port can be greater than a maximum height defined by the base and body of the first vascular access port. | 2019-09-05 |
| 20190269843 | EXTRACORPOREAL PHOTODYNAMIC BLOOD ILLUMINATION (IRRADIATION) FOR THE TREATMENT OF CARBON MONOXIDE POISONING - Treatment of carbon monoxide poisoning of a body by removal of a portion of the blood from the body, placing the portion in an exposure cell, exposing the portion in the cell to light of wave length and intensity that causes dissociation of carbon monoxide from hemoglobin, and returning the portion to the body. The intensity and wave length of the light is sufficient to dissociate a therapeutically-effective amount of carbon monoxide from the hemoglobin in the blood. The blood is circulated from and to the body through a concentric double lumen cannula. The wave lengths of the light are 540 and/or 570 nanometers. The cell exposes the blood to at least 9.5 Joules of dissociative light per milliliter of blood, and least 9.5 Watts of dissociative light per milliliter of blood per second. Oxygen is provided to, and the dissociated carbon monoxide is removed from the system. | 2019-09-05 |
| 20190269844 | Systems And Methods For Performing Online Extracorporeal Photopheresis - Systems and methods for performing online extracorporeal photopheresis of mononuclear cells are disclosed. During a mononuclear cell collection cycle, blood is removed from a source and separated into a plasma constituent, a mononuclear cell-containing layer, and red blood cells, followed by the collection of a pre-product including at least a portion of the mononuclear cell-containing layer and at least a portion of the separated red blood cells. The mononuclear cell collection cycle may be repeated, followed by the production of a single mononuclear cell product using the collected pre-product(s). The mononuclear cell product is irradiated using a fixed dose of light, such that the mononuclear cell product is produced so as to have a predetermined volume and a predetermined hematocrit, regardless of the number of pre-products used to produce the mononuclear cell product. Following irradiation, at least a portion of the irradiated mononuclear cell product is returned to the source. | 2019-09-05 |
| 20190269845 | Combination Suction and Irrigation Hand Tool - An irrigation fluid dispensing tool well suited for use in a combination suction and irrigation tool has a frame carrying a surge flow pump formed of a flow controller of a manipulable handgrip of the tool handle, compressible irrigation fluid reservoir, and frame where the flow controller preferably is formed of a handle lever of the handgrip that is displaceable, preferably pivotable, between one or more of a surge flow actuation position, flow obstructing actuation position, and flow initiating position. The lever actuates a valve, preferably a pinch valve, when displaced toward the flow obstructing actuation position. The lever actuates the surge pump by compressing the reservoir, preferably squeeze bulb, against the frame when the handgrip is squeezed. The lever can be assembled to the frame in a protective shipping and storage position and is movable to a tool operating position providing irrigation fluid flow control during tool operation. | 2019-09-05 |
| 20190269846 | INFUSION SYSTEM WHICH UTILIZES ONE OR MORE SENSORS AND ADDITIONAL INFORMATION TO MAKE AN AIR DETERMINATION REGARDING THE INFUSION SYSTEM - In one step of a method for infusing an infusion fluid, the infusion fluid is pumped through a fluid delivery line of an infusion system. In another step, measurements are taken with at least one sensor connected to the infusion system. In an additional step, an air determination is determined with at least one processor. The air determination is related to air in the fluid delivery line. The air determination is based on the measurements taken by the at least one sensor. The air determination is further based on: (1) medication information regarding the infusion fluid or infusion information regarding the infusion of the infusion fluid; or (2) multi-channel filtering of the measurements from the at least one sensor or non-linear mapping of the measurements from the at least one sensor; and statistical process control charts applied to the multi-channel filtered measurements or applied to the non-linear mapped measurements. | 2019-09-05 |
| 20190269847 | PUMP SYSTEMS WITH POSITIONING FEATURES - Pump systems are described. An example pump system may include a processing unit and a recess configured to receive a pump cartridge. The recess can include a plurality of cartridge engagement slots. The cartridge engagement slots can be configured for removably coupling the pump cartridge. The recess can also include a cartridge-facing surface with a positioning feature slot extending orthogonal to a general plane of the cartridge-facing surface. | 2019-09-05 |
| 20190269848 | IV Extension Set or IV Set System with Bypass Manifold - An intravenous (IV) set system comprising a primary IV set having a plurality of access points facilitating access to one or more fluid pathways of the primary IV set, and an IV extension set removably coupled to the primary IV set to form an extended primary IV set, the IV extension set comprising an extension flow line defining an extension flow path, and a plurality of access ports on the extension flow line, at least two of the access ports comprising access ports located between first and second ends of the IV extension set. The IV set system further comprises a bypass manifold externally and removably coupled to the extension flow line of the IV extension set via the intermediate access ports on the extension flow line, the bypass manifold comprising a bypass flow line adjacent the extension flow line, and one or more access points that facilitate access to the bypass flow line, wherein the bypass manifold and the bypass flow line are operable to provide a bypass flow path through the IV extension so. | 2019-09-05 |
| 20190269849 | OCCLUSION DETECTION SYSTEM AND METHOD - A method, computer program product, and infusion pump assembly for determining a first rate-of-change force reading that corresponds to the delivery of a first dose of an infusible fluid via an infusion pump assembly. At least a second rate-of-change force reading is determined that corresponds to the delivery of at least a second dose of the infusible fluid via the infusion pump assembly. An average rate-of-change force reading is determined based, at least in part upon the first rate-of-change force reading and the at least a second rate-of-change force reading. | 2019-09-05 |
| 20190269850 | IMPLANTABLE CONTINUOUS-FLOW PUMPS - In various embodiments, a drug pump includes a housing and, within the housing, an expandable drug reservoir at least part of which is exposed to a pressurized propellant. The propellant exerts a substantially constant pressure on the drug reservoir. A flow restrictor significantly limits outflow from the pump, and preferably has both a small diameter and a long path length, which acts to control the outflow from the drug reservoir. As a result, the pump produces a substantially constant outflow. | 2019-09-05 |
| 20190269851 | Fluid Exchange Catheter System - A method of delivering a solution including at least one drug is provided. The method includes providing a fluid exchange catheter system which includes an inner lumen, the proximal end of which is connected to an infusion mechanism configured to control infusion of a solution that includes at least one drug, and an outer lumen, the proximal end of which is connected to an aspiration mechanism configured to control aspiration of fluid from the body. The method also includes activating the infusion mechanism to infuse the solution into the body for a first infusion time period and at a first infusion pressure, disabling the infusion mechanism to stop infusion, and activating the aspiration mechanism to aspirate fluid for a first aspiration time period and at a first aspiration pressure. Also described is a method of unblocking a fluid exchange catheter. | 2019-09-05 |
| 20190269852 | MATCHING DELAYED INFUSION AUTO-PROGRAMS WITH MANUALLY ENTERED INFUSION PROGRAMS - A system and method that identifies delayed infusion programs at an infusion pump or with a first computer and an infusion pump. The first computer receives an infusion auto-program from a remote source, transmits the infusion auto-program to the infusion pump, and sends a stale auto-program to the infusion pump. The infusion pump receives a manual infusion program, saves and executes the manual infusion program, and compares the stale auto-program to the manual infusion program to identify potential matches between the stale auto-program and the manual infusion program. The infusion pump evaluates the potential matches and determines if the potential matches are within a predefined tolerance, continues to execute the at least one manual infusion program on the infusion pump if the potential matches are within the predefined tolerance, and remotely saves differences in the manual infusion program and the at stale auto-program in a remote server for later analysis. | 2019-09-05 |
| 20190269853 | METHODS AND SYSTEMS FOR DETERMINING FLUID ADMINISTRATION - Methods and systems are provided for determining fluid administration. The system may determine fluid administration based on the fluid responsiveness and regional oxygen saturation of a subject. The system may receive the fluid responsiveness and regional oxygen saturation from external sources or may determine one or both based on received physiological signals. In some embodiments, the system may determine whether to administer fluid based on the fluid responsiveness and regional oxygen saturation. In some embodiments, the system may determine the amount of fluid to administer based on the fluid responsiveness and regional oxygen saturation. In some embodiments, the system may determine the effectiveness of fluid administration. In some embodiments, the system may provide an indication of the determined fluid administration so that a care-giver can implement the appropriate fluid administration. In some embodiments, the system may control the fluid administration based on its determination. | 2019-09-05 |
| 20190269854 | DEVICE FOR TREATING AN INDIVUDUAL SUFFERING FROM CARDIAC INSUFFICIENCY, CARDIAC ARREST, CIRCULATORY ARREST OR STROKE - The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR). | 2019-09-05 |
| 20190269855 | Housing for an Injection Device - A housing includes a body and a cartridge holder. The body can accommodate a drive mechanism including a piston rod to operably engage with a piston of a cartridge filled with a liquid injectable medicament. The cartridge holder has a cartridge receiving space. The cartridge holder has an insert section at a proximal end. The body has a receptacle to receive the insert section. The cartridge holder includes a first latch element located on the insert section. The body includes a second latch element located in the receptacle and protruding inwardly from a side wall section of the receptacle. A radial extension of the first latch element is less than a thickness of the side wall of the insert section or of the receptacle. A radial protrusion of the second latch element is less than a thickness of the side wall sections of the insert section or of the receptacle. | 2019-09-05 |
| 20190269856 | Feedback Mechanism for an Injection Device - A feedback mechanism for an injection device that is configured to deliver a medicament to a user is described. The feedback mechanism has a biasing member that is arranged to apply a force to a delay element, and the delay element is configured to deform and/or break under the force. The feedback mechanism also includes an indicator arranged to generate user feedback after the delay element is deformed and/or broken. The delay element is configured to deform and/or break at a time after the force is applied by the biasing member to create a delay before the user feedback is generated. | 2019-09-05 |
| 20190269857 | Manually-Actuated Injection Device for High-Viscosity Drugs - A manually actuated drug-injecting device is configured such that the grip strength of the entire hand (i.e., majority of fingers closing toward the palm or heel of the hand) is employed to discharge medication through a hypodermic needle and into a patient's body. The device is well suited for delivering medications with high viscosity and/or by patients (e.g., elderly patients) with reduced finger strength and dexterity. The device includes a grip member, a push member (which causes the medication to be injected), and a force-transfer mechanism that couples the grip member to the push member. Suitably, the device is configured to be held transverse to the palm of the medication-administering hand, with a discharge port located by the outer, blade edge of the administering hand, when the device is being gripped to administer medication. | 2019-09-05 |
| 20190269858 | MULTI-CHANNEL ROTARY ENCODER - A rotary encoder includes a substrate, two or more switches disposed on the substrate, a mechanical wave generator, and a controller. The mechanical wave generator is disposed proximate to the substrate. The substrate and the mechanical wave generator are adapted to rotate relative to each other about a central axis. The mechanical wave generator has a profile shape that repeats circumferentially about the central axis. The profile shape has ridges and valleys that engage the two or more switches to activate and deactivate the two or more switches as the substrate and the mechanical wave generator rotate relative to each other. The controller is electrically coupled to the two or more switches to track activations of the two or more switches and digitally encode a rotational position of the substrate relative to the wave generator based upon the activations. | 2019-09-05 |
| 20190269859 | DRUG INJECTION DEVICE WITH DEFLECTABLE HOUSING PORTION - The present invention provides a drug injection device ( | 2019-09-05 |
| 20190269860 | SINGLE SLIDER DOUBLE BARREL SYRINGE AND METHOD TO USE SAME FOR MEDICAL DIAGNOSTICS, THERAPEUTIC USE, AND PLACEMENT CONFIRMATION AND JOINT SPACE INJECTION - A syringe is provided having a hub with an orifice, first and second barrels having interior surfaces to form respective lumens, a slider, and an optional test indicator. The first and second barrels slideably receive respective first and second plungers for movement therein. The slider is operable to provide a fluidly communicative path between the orifice of the hub and the first and second barrel lumens. The optional test indicator is responsive to at least one characteristic of bodily fluid, the test indicator positioned to be exposed to any bodily fluid drawn into the first barrel lumen and visible from an exterior of the first barrel. | 2019-09-05 |
| 20190269861 | APPARATUS AND METHODS FOR MEASURING PERIPHERAL VENOUS PRESSURE AND APPLICATIONS OF SAME - A method of measuring peripheral venous pressure includes providing a tubing operably connected between a fluid source and a vein, a fluid controlling device for occluding the tubing and configured to have an on position and an off position, and at least one pressure sensor in fluid communication with the tubing, placed between the fluid controlling device and the vein; selectively passing fluid from the fluid source to the vein, through the tubing, by the fluid controlling device; measuring both a fluid pressure from the fluid source and a distal venous pressure from the vein by the at least one pressure sensor when the fluid controlling device is in the on position; and measuring the distal venous pressure from the vein only by the at least one pressure sensor when the fluid controlling device is in the off position. | 2019-09-05 |
| 20190269862 | Patch-Sized Fluid Delivery Systems and Methods - A patch-sized fluid delivery device may include a reusable portion and a disposable portion. The disposable portion may include components that come into contact with the fluid, while the reusable portion may include only components that do not come into contact with the fluid. Redundant systems, such as redundant controllers, power sources, motor actuators, and alarms, may be provided. Alternatively or additionally, certain components can be multi-functional, such a microphones and loudspeakers that may be used for both acoustic volume sensing and for other functions and a coil that may be used as both an inductive coupler for a battery recharger and an antenna for a wireless transceiver. Various types of network interfaces may be provided in order to allow for remote control and monitoring of the device. | 2019-09-05 |
| 20190269863 | AUTOMATIC SMOKE EVACUATOR AND INSUFFLATION SYSTEM FOR SURGICAL PROCEDURES - An automatic smoke evacuation and insufflation system for surgical procedures having a vacuum for removing gas, smoke, and debris from a surgical site and an insufflator for supplying gas to the body cavity of a patient. | 2019-09-05 |
